Abbott Laboratories

NYSE:ABT Lagerbericht

Marktkapitalisierung: US$152.9b

Abbott Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Abbott Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 12.6% bzw. 8.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 22.4% betragen.

Wichtige Informationen

12.6%

Wachstumsrate der Gewinne

12.58%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum16.1%
Wachstumsrate der Einnahmen8.2%
Zukünftige Eigenkapitalrendite22.39%
Analystenabdeckung

Good

Zuletzt aktualisiert11 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Narrativ-Update • May 12

ABT: Medtech Pipeline And Dividend Record Will Support Future Repricing

Analysts have trimmed Abbott Laboratories' consolidated price target by $1, reflecting a slightly higher discount rate, a marginally lower revenue growth outlook, a very small adjustment to profit margin assumptions, and a modestly lower future P/E multiple in light of several recent target cuts and a removal from a conviction list. Analyst Commentary Recent Street research on Abbott Laboratories has tilted more cautious, with a series of price target reductions and a removal from a major conviction list.
Seeking Alpha • May 09

Abbott Laboratories Is On Sale, Don't Overlook It

Summary Abbott Laboratories is trading at a 27% discount to fair value, offering a compelling entry point for long-term investors. ABT's Medical Devices and Diagnostics segments drive robust growth, with the Exact Sciences acquisition adding market-leading oncology diagnostics. Consensus forecasts 9.1% annual EPS growth through 2028, supporting continued 7%-8% dividend growth and a 54-year streak. Litigation over infant formula and Exact Sciences' integration pose risks, but ABT's fundamentals and earnings growth underpin a projected 45% upside by 2027. Read the full article on Seeking Alpha
Narrativ-Update • Apr 23

ABT: AF Portfolio And Dividend Track Record Will Support Future Repricing

Analysts have trimmed Abbott Laboratories' implied fair value estimate to $118.64 from $131.44. This reflects a series of recent price target reductions as they factor in updated growth, margin and P/E assumptions.
Narrativ-Update • Apr 09

ABT: AF Portfolio And Dividend Track Record Will Support Future Upside

Abbott Laboratories' updated analyst price target reflects a modest reset, with fair value moving from $132.64 to $131.44 as analysts factor in higher assumed revenue growth of 10.24%, a lower profit margin of 15.60% and a slightly richer future P/E of 30.91x. Analyst Commentary Recent research on Abbott Laboratories points to an active debate around how much investors should pay for the stock, with several price target changes clustered over the past few months.
Narrativ-Update • Mar 26

ABT: AF Portfolio Advancements And Dividend Streak Will Support Future Upside

Analysts have trimmed Abbott Laboratories' fair value estimate by about $0.70 to $132.64. This reflects a series of recent target cuts across the Street, even as they continue to reference generally healthy medtech sector fundamentals.
Narrativ-Update • Mar 11

ABT: AF Portfolio Progress And Dividend Streak Will Drive Future Upside

Analysts have trimmed their average price targets on Abbott Laboratories by a few dollars, reflecting slightly higher required returns and refreshed assumptions on fair value, while still grounding their views in recent research that includes both target cuts and at least one upward revision. Analyst Commentary Recent research on Abbott Laboratories gives you a mixed but useful read on how the Street is thinking about valuation, execution, and growth.
Narrativ-Update • Feb 24

ABT: Exact Sciences Deal And AF Portfolio Will Reshape Future Upside

Analyst targets on Abbott Laboratories have moved lower by double digit dollar amounts, with multiple firms trimming their price objectives in U.S. dollars as they factor in updated assumptions on discount rates, long term revenue growth, margins and future P/E expectations. Analyst Commentary Recent Street research on Abbott Laboratories reflects a mix of caution on valuation and optimism around the company’s longer term positioning, with several firms resetting price targets and one firm upgrading the stock.
Narrativ-Update • Feb 10

ABT: Exact Sciences Deal Will Reshape Testing Franchise And Future Upside

Analysts have trimmed their fair value estimate for Abbott Laboratories by about $3 to roughly $133. This reflects modestly softer revenue growth assumptions, a slightly lower future P/E multiple near 30x, and recent reductions in price targets across several firms, even as some still highlight the pending Exact Sciences deal as a key part of their thesis.
Narrativ-Update • Jan 26

ABT: Exact Sciences Acquisition Will Shape Future Earnings Mix And Upside Potential

Analysts have reduced their fair value estimate for Abbott Laboratories by about $8 to $136.47, reflecting a series of recent price target cuts that incorporate slightly adjusted growth, discount rate and P/E assumptions, along with expectations for a modestly higher profit margin profile. Analyst Commentary Recent research updates show a mix of optimism and caution around Abbott Laboratories, with several firms adjusting price targets and factoring in the pending Exact Sciences acquisition.
Narrativ-Update • Jan 11

ABT: Exact Sciences Deal And Legal Wins Will Support Future Upside

Narrative Update Overview The updated analyst work on Abbott Laboratories reflects a small increase in the implied fair value to about $144.75. Analysts point to a tighter discount rate, steady growth and margin assumptions, and a blended view of recent price target changes that factor in medical devices momentum, the pending Exact Sciences deal, and reduced legal overhangs.
Analyseartikel • Jan 03

Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
Narrativ-Update • Dec 27

ABT: Exact Sciences Deal And Legal Wins Will Drive Future Returns

Analysts modestly raised their average price target for Abbott Laboratories to about $144 per share, citing resilient mid-single digit organic revenue growth, double digit earnings power supported by a diversified healthcare portfolio, accelerating momentum in Medical Devices despite some near term lumpiness, and potential strategic upside from the pending Exact Sciences acquisition at a premium takeout valuation. Analyst Commentary Street research remains broadly constructive on Abbott, with recent notes highlighting both upside drivers and areas of near term scrutiny as investors digest the Exact Sciences transaction and mixed quarterly optics.
Narrativ-Update • Dec 12

ABT: Exact Sciences Deal And Legal Wins Will Drive Future Upside

Analysts made a modest adjustment to their Abbott Laboratories price targets, with estimates moving in a roughly $2 range around the mid-$140s as they balanced optimism around the pending Exact Sciences acquisition, resilient device driven growth, and favorable legal developments against some near term lumpiness in non device segments. Analyst Commentary Research coverage around Abbott remains largely constructive, with most views anchored on a durable devices growth profile, incremental benefits from the proposed Exact Sciences transaction, and diminishing legal overhangs.
Narrativ-Update • Nov 28

ABT: Exact Sciences Acquisition And Legal Wins Will Drive Medium-Term Upside

Abbott Laboratories’ analyst price target saw a modest decrease to $144.43 as analysts point to shifting expectations around profit margin and a slightly higher discount rate. This development is tempered by optimism for ongoing revenue growth and stability in core medical device performance.
Narrativ-Update • Nov 14

ABT: Momentum From Legal Win And Product Approvals Will Support Future Gains

Analysts have modestly revised their price targets for Abbott Laboratories, with recent updates ranging from $142 to $146 per share. They cite strong momentum in Medical Devices and a resilient, diversified business model, despite varied performance across business segments.
Analyseartikel • Nov 05

Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem

Abbott Laboratories ( NYSE:ABT ) announced strong profits, but the stock was stagnant. Our analysis suggests that...
Narrativ-Update • Oct 31

ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead

Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.
Narrativ-Update • Oct 16

Expanding Emerging Markets And Diagnostics Will Drive Prospects Despite Headwinds

Analysts have modestly increased their price target for Abbott Laboratories from $142.48 to $144.40, citing resilient growth in medical devices and expectations for steady double-digit earnings growth, even though there may be some near-term variability across business segments. Analyst Commentary Recent research notes reflect a mix of optimism and caution from analysts following Abbott Laboratories' latest results and updates to price targets.
Analyseartikel • Sep 15

There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings

With a price-to-earnings (or "P/E") ratio of 16.7x Abbott Laboratories ( NYSE:ABT ) may be sending bullish signals at...
Seeking Alpha • Apr 16

Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices

Summary I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth and 8.3% growth excluding COVID testing, driven by 12.6% growth in medical devices and 7.8% in pharma. Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and drive future growth. Despite geopolitical risks in China, Abbott's cost management and margin expansion support the ABT stock double-digit EPS growth guidance for FY25. Read the full article on Seeking Alpha
Seeking Alpha • Mar 16

Abbott Laboratories Basking In A Sharp Turn In Sentiment

Summary Abbott Laboratories' stock has surged 25% in eight months, outperforming peers on strong medical device growth and perhaps market rotation to names with less perceived macro and geopolitical risk. Fourth quarter results showed 9% organic revenue growth, with medical devices leading at 14%, and improved profit margins. Abbott's medical device business is executing well, with double-digit growth in structural heart and diabetes, and above-peer results across most of the business. An important legal victory could signal lower overall risk in its infant nutrition litigation, while a lackluster trial result from a rival could re-energize the outlook for TriClip. Valuation is more challenging now, as it takes a pretty aggressive bull-case model to find significant fundamentals-driven upside. Read the full article on Seeking Alpha
Seeking Alpha • Jan 23

Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)

Summary Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month. The company looks set up to deliver double-digit annual adjusted diluted EPS growth for the foreseeable future. Abbott Laboratories enjoys an AA- credit rating from S&P on a stable outlook. Shares of the healthcare stock appear to be modestly discounted. Abbott Laboratories could be positioned for 10% annual total returns by the end of 2027. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NYSE:ABT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202858,7279,23010,39112,63718
12/31/202754,8188,1689,43811,44124
12/31/202650,2987,0198,62710,66424
3/31/202645,1346,2527,3789,464N/A
12/31/202544,3286,5007,3959,566N/A
9/30/202543,84313,9756,9179,119N/A
6/30/202543,10913,9776,7759,037N/A
3/31/202542,34413,5006,6578,950N/A
12/31/202441,95013,4006,3518,558N/A
9/30/202441,2175,7616,4868,728N/A
6/30/202440,7255,5465,6547,900N/A
3/31/202440,3265,6084,9237,143N/A
12/31/202340,1095,7005,0597,261N/A
9/30/202339,9595,1424,4926,549N/A
6/30/202340,2265,1405,4887,452N/A
3/31/202341,5055,7856,8238,659N/A
12/31/202243,6536,9057,8049,581N/A
9/30/202245,0307,8578,54110,322N/A
6/30/202245,5488,5208,46810,243N/A
3/31/202244,5147,6958,1529,961N/A
12/31/202143,0757,0428,64810,533N/A
9/30/202142,3087,2089,31411,264N/A
6/30/202140,2336,3438,64410,629N/A
3/31/202137,3385,6937,6099,823N/A
12/31/202034,6084,4495,7247,901N/A
9/30/202032,2213,3464,5876,519N/A
6/30/202031,4443,0734,5646,401N/A
3/31/202032,0953,5394,4766,139N/A
12/31/201931,9043,666N/A6,136N/A
9/30/201931,3553,272N/A5,485N/A
6/30/201930,9352,867N/A5,720N/A
3/31/201930,7232,582N/A5,904N/A
12/31/201830,5782,319N/A6,300N/A
9/30/201830,402802N/A6,175N/A
6/30/201829,575812N/A5,997N/A
3/31/201828,445365N/A6,104N/A
12/31/201727,390344N/A5,570N/A
9/30/201725,1341,971N/A5,100N/A
6/30/201723,6071,055N/A4,312N/A
3/31/201722,3031,384N/A3,870N/A
12/31/201620,8531,056N/A3,203N/A
9/30/201620,708989N/A2,861N/A
6/30/201620,5561,939N/A2,839N/A
3/31/201620,3932,124N/A2,871N/A
12/31/201520,4052,586N/A2,966N/A
9/30/201520,5732,523N/A3,376N/A
6/30/201520,5022,365N/A3,382N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ABTDas prognostizierte Gewinnwachstum (12.6% pro Jahr) liegt über der Sparquote (3.5%).

Ertrag vs. Markt: ABTDie Erträge des Unternehmens (12.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (16.8% pro Jahr).

Hohe Wachstumserträge: ABTDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: ABTDie Einnahmen des Unternehmens (8.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).

Hohe Wachstumseinnahmen: ABTDie Einnahmen des Unternehmens (8.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ABTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (22.4%)

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/22 04:22
Aktienkurs zum Tagesende2026/05/22 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Abbott Laboratories wird von 52 Analysten beobachtet. 24 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
David ToungArgus Research Company
Adam FeinsteinBarclays
Matthew MiksicBarclays